Inicio de sesión



Dr. Albert Adell

Phone: (+34) 942 206857/ Fax : (+34) 942 266399
Mailing address: IBBTEC. C/ Albert Einstein 22, PCTCAN, 39011 Santande​r

Systems Neurobiology


Principal Investigator

Dr. Albert Adell​


  • Raquel Pascual Antón, predoctoral


Research interests

To study the effects of new fast-acting antidepressant treatments (deep brain stimulation [DBS], ketamine, subunit selective NMDA receptor antagonists) on the changes produced in animal models of depression. This includes the study in detail of the role of the projections from the prefrontal cortex to the monoaminergic nuclei of the brainstem in the pathophysiology of depression and its pharmacological treatment.



  • Instituto de Salud Carlos III, Subdirección General de Evaluación y Fomento de la Investigación (FIS Grants PI10-01103 and PI13-00038) that were co-funded by the European Regional Development Fund ("A way to build Europe").
  • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)

Relevant publications (last 10 years)

  • Characterization of oscillatory changes in hippocampus and amygdala after deep brain stimulation of the infralimbic prefrontal cortex. Cervera-Ferri A, Teruel-Martí V, Barceló-Molina M, Martínez-Ricós J, Luque-García A, Martínez-Bellver S, Adell A.
    Physiol Rep
    . 2016 Jul;4(14). pii: e12854. doi: 10.14814/phy2.12854. [PubMed]

  • Behavioral, neurochemical and molecular changes after acute deep brain stimulation of the infralimbic prefrontal cortex.
    Jiménez-Sánchez L, Linge R, Campa L, Valdizán EM, Pazos Á, Díaz Á, Adell A.
    . 2016 Sep;108:91-102. doi: 10.1016/j.neuropharm.2016.04.020. [PubMed]

  • Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.
    Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á.
    . 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017. [PubMed]

  • Activation of AMPA Receptors Mediates the Antidepressant Action of Deep Brain Stimulation of the Infralimbic Prefrontal Cortex.
    Jiménez-Sánchez L, Castañé A, Pérez-Caballero L, Grifoll-Escoda M, López-Gil X, Campa L, Galofré M, Berrocoso E, Adell A.
    Cereb Cortex
    . 2016 Jun;26(6):2778-89. doi: 10.1093/cercor/bhv133. [PubMed]
  • Revisiting the role of raphe and serotonin in neuropsychiatric disorders. Adell A.
    (2015) J Gen Physiol 145: 257-259. [PubMed]
  • The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression. Jiménez-Sánchez L., Campa L., Auberson Y.P. and Adell A.
    (2014) Neuropsychopharmacology 39, 2673–2680
    . [PubMed]​
  • Blockade of MK-801-induced heat shock protein 72 in rat brain by antipsychotic and monoaminergic agents targeting D2, 5-HT1A, 5-HT2A and α1-adrenergic receptors. Romón T., Planas A.M. and Adell A.
    CNS Neurol. Disord. – Drug Targets 13: 104-111. [PubMed]
  • Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Mocci G., Jiménez-Sánchez L., Adell A. and Artigas F.
    Neuropharmacology 79: 49-58. [PubMed]
  • Role of prefrontal cortex in the pathophysiology and treatment of depression and schizophrenia. In: Neurobiology of Mood Disorders. López-Gil X., Jiménez-Sánchez L. and Adell A.
    (2013) Guiard B.P. and Dremencov E. (Eds.). Bentham Science Publishers, Sharjah, pp. 139-173.
  • Importance of interhemispheric prefrontal connection in the effects of noncompetitive NMDA receptor antagonists. López-Gil X., Jiménez-Sánchez L., Romón T., Campa L., Artigas F. and Adell A.
    Int. J. Neuropsychopharmacol. 15: 945-956. [PubMed]
  • Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Adell A., Jiménez-Sánchez L., López-Gil X. and Romón T.
    Schizophrenia Bull. 38: 9-14. [PubMed]
  • Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia. Romón T., Mengod G. and Adell A.
    Psychopharmacology 217: 231-238. [PubMed]
  • Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. Adell A.
    Idrugs 13: 900-910. [PubMed]
  • Microdialysis. Adell A. and Artigas F.
    (2010) In: Encyclopedia of Psychopharmacology. Stolerman I.P. (Ed.). Springer-Verlag, Berlin, pp. 769-775.
  • In vitro and in vivo activation of astrocytes by amyloid β is potentiated by pro-oxidant agents. García-Matas S., de Vera N., Ortega-Aznar A., Marimon J.M., Adell A., Planas A.M., Cristòfol R. and Sanfeliu C.
    J. Alzheimer's Dis. 20: 229-245. [PubMed]
  • Serotonin interaction with other transmitter systems. In: Handbook of Behavioral Neurobiology of Serotonin. Adell A., Bortolozzi A., Díaz-Mataix L., Santana N. and Artigas F.
    (2010) Müller C.P. and Jacobs B.L. (Eds.). Elsevier, Amsterdam, pp. 259-276.
  • Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. López-Gil X., Artigas F. and Adell A.
    Curr. Pharm. Des. 16: 502-515. [PubMed]
  • New strategies in the search of antipsychotic drugs. Adell A.
    Curr. Pharm. Des. 16: 486-487. [PubMed]
  • Role of prefrontal cortex in pharmacological models of schizophrenia and antipsychotic action. Celada P., Adell A., López-Gil X., Kargieman L., Santana N., Bortolozzi A., Castañé A. and Artigas F.
    (2009) Eur. J. Psychiatry 23 (Suppl.): 17-24.
  • Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. López-Gil X., Artigas F. and Adell A.
    Int. J. Neuropsychopharmacol. 12: 487-499. [PubMed]
  • Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Pertusa M., García-Matas S., Mammeri H., Adell A., Rodrigo T., Mallet J., Cristòfol R., Sarkis C. and Sanfeliu C.
    Neurobiol. Aging 29: 1366-1379. [PubMed]
  • Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. López-Gil X., Babot Z., Amargós-Bosch M., Suñol C., Artigas F. and Adell A.
    Neuropsychopharmacology 32: 2087-2097. [PubMed]
  • Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex. Amargós-Bosch M., Adell A. and Artigas F.
    J. Neurochem. 102: 550-561. [PubMed]
  • Modeling schizophrenia in experimental animals. In: Antidepressants, Antipsychotics, Anxiolytics. From Chemistry and Pharmacology to Clinical Application. Celada P., Castañé A., Adell A. and Artigas F. (2007)
    Vol. 1. Buschmann H., Díaz J.L., Holenz J., Párraga A., Torrens A. and Vela J.M. (Eds.). Wiley-Vch, Weinheim, pp. 449-489.
  • The use of brain microdialysis in antidepressant drug research. In: Handbook of Microdialysis, Methods, Applications and Clinical Aspects. Artigas F. and Adell A.
    (2007) Westerink B.H.C. and Cremers T.I.F.H. (Eds.). Elsevier/Academic Press, Amsterdam, pp. 527-543.
  • Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in medial prefrontal cortex elicited by phencyclidine and ketamine. Amargós-Bosch M., López-Gil X., Artigas F. and Adell A.
    Int. J. Neuropsychopharmacol. 9: 565-573. [PubMed]
  • Modulation of the neuronal activity and neurotransmitter release by 5-HT1A and 5-HT1B/1D receptors. Celada P., Adell A. and Artigas F.
    (2006) In: The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics. Roth B.L. (Ed.). Humana Press, Totowa, pp. 365-402.
  • Pindolol augmentation of antidepressant response. Artigas F., Adell A. and Celada P.
    Curr. Drug Targets 7: 139-147. [PubMed]
  • Akzeleration der antidepressiva-response und augmentation mit pindolol. In: Acute und Therapieresistente Depressionen. Artigas F., Adell A. and Celada P.
    (2005) Bauer M., Berghöfer A. and Adli M. (Eds.). Springer, Heidelberg, pp. 285-298.
  • Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Amargós-Bosch M., Artigas F. and Adell A.
    Eur. J. Pharmacol. 516: 235-238. [PubMed]
  • BDNF modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. Pineda J.R., Canals J.M., Bosch M., Adell A., Mengod G., Artigas F., Ernfors P. and Alberch J.
    J. Neurochem. 93: 1057-1068. [PubMed]
  • Strategies for producing more rapidly acting antidepressants. Adell A., Castro E., Celada P., Bortolozzi A., Pazos A. and Artigas F.
    Drug Discov. Today 10: 578-585. [PubMed]
  • The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Adell A. and Artigas F.
    Neurosci. Biobehav. Rev. 28: 415-431. [PubMed]
  • The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. Celada P., Puig M.V., Amargós-Bosch M., Adell A. and Artigas F.
    J. Psychiatry Neurosci. 29: 252-265. [PubMed]
  • Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Adell A.
    Curr. Drug Targets CNS Neurol. Disord. 3: 113-121. [PubMed]
  • In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice. Bortolozzi A., Amargós-Bosch M.; Toth M., Artigas F. and Adell A.
    J. Neurochem. 88: 1373-1379. [PubMed]
  • Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Amargós-Bosch M., Bortolozzi A., Puig M.V., Serrats J., Adell A., Celada P., Toth M., Mengod G. and Artigas F.
    Cereb. Cortex 14: 281-299. [PubMed]​